Quick navigation menu :
  1. Go to content
  2. Go to the main sections menu
  3. Go to the subsections menu
  4. Go to the search engine
  5. Go to the languages menu
  6. Go to the help menu
  7. Go to contact slot
You are here:
  1. Home
  2. > Press room
  3. > Press releases
  4. > Year 2006
Languages menu :
 

Contacts

Press Relations
Tel. :
(33) 1 53 77 4450
Fax :
(33) 1 53 77 4622
Adress :
174, avenue de France
75013 PARIS
FRANCE
Switchboard :
(33) 1 53 77 4000
Content :

Press releases

WarningPress releases and press packs are intended to journalists, investors and shareholders. 

Paris, France  October 17, 2006

Sanofi-aventis has sold its entire stake in Rhodia

Sanofi-aventis confirms that it has sold to BNP Paribas its entire stake in the capital of Rhodia representing 96,110,182 shares, for a total consideration of €183 million, in the context of a firm purchase agreement with a view to resale to institutional investors in a private placement.

About sanofi-aventis

Sanofi-aventis is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

The securities offered will not be or have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the Securities Act.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include the those related to the fulfillment of the general conditions to the transaction described in this press release. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statement.

© sanofi-aventis 2004-2008 | Legal notice | Update: December 21, 2007